Solid Biosciences (SLDB) Payables: 2017-2024
Historic Payables for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to $3.5 million.
- Solid Biosciences' Payables rose 82.19% to $3.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $9.7 million, marking a year-over-year decrease of 28.89%. This contributed to the annual value of $2.0 million for FY2023, which is 37.25% down from last year.
- Solid Biosciences' Payables amounted to $3.5 million in Q3 2024, which was up 37.17% from $2.5 million recorded in Q2 2024.
- Solid Biosciences' Payables' 5-year high stood at $5.6 million during Q1 2023, with a 5-year trough of $1.7 million in Q1 2024.
- Moreover, its 3-year median value for Payables was $3.2 million (2022), whereas its average is $3.5 million.
- The largest annual percentage gain for Solid Biosciences' Payables in the last 5 years was 82.19% (2024), contrasted with its biggest fall of 69.08% (2024).
- Quarterly analysis of 5 years shows Solid Biosciences' Payables stood at $3.3 million in 2020, then spiked by 36.32% to $4.5 million in 2021, then decreased by 27.45% to $3.2 million in 2022, then tumbled by 37.25% to $2.0 million in 2023, then skyrocketed by 82.19% to $3.5 million in 2024.
- Its last three reported values are $3.5 million in Q3 2024, $2.5 million for Q2 2024, and $1.7 million during Q1 2024.